



## Does higher major bleeding lead to higher mortality - Significance of Fondaparinux in reducing bleeding.

- The reduction in bleeding has a considerable effect on the rate of ischemic events, with a significant reduction in death<sup>(1)</sup> .
- The OASIS-5 trial demonstrated that Fondaparinux, compared with Enoxaparin for treatment of non–ST segment elevation acute coronary syndromes, reduced major bleeding by 48% at 9 days, which was associated with a 17% mortality reduction at 30 days<sup>(2)</sup>.

### Reference:

1. Vasc Health Risk Manag. 2010; 6: 179–187.

2. N Engl J Med 2006;354:1464-76